Silver Nitrate-Coated Versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial

Joseph B Shrager; Rahul Bhatnagar; Christine T Kearney; Nathan P Retzlaff; Evan Cohen; Andrew E Stanton; Colleen Keyes; Momen M Wahidi; Colin Gillespie; Najib Rahman; Anthony L Kerry; David Feller-Kopman; Daniel Nader; Jason Akulian; Alex Chen; Mark Berry; Adnan Majid; Chakravarthy Reddy; Alain Tremblay; Nick A Maskell

doi:10.1513/AnnalsATS.202111-1301OC

Silver Nitrate-Coated Versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial

Joseph B Shrager^*
, Rahul Bhatnagar
, Christine T Kearney
, Nathan P Retzlaff
, Evan Cohen
, Andrew E Stanton
, Colleen Keyes
, Momen M Wahidi
, Colin Gillespie
, Najib Rahman
, Anthony L Kerry
, David Feller-Kopman
, Daniel Nader
, Jason Akulian
, Alex Chen
, Mark Berry
, Adnan Majid
, Chakravarthy Reddy
, Alain Tremblay
, Nick A Maskell

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

15 Citations (Scopus)

159 Downloads (Pure)

Abstract

RATIONALE: Tunneled, indwelling pleural catheters (IPC) have been demonstrated to be an effective method of managing malignant pleural effusions. However, they allow pleurodesis and can therefore be removed in only a subset of patients. A novel, silver-nitrate coated IPC was developed with the intention of creating a rapid, effective chemical pleurodesis to allow more frequent and earlier catheter removal. This study represent the pivotal clinical trial evaluating that catheter vs the standard IPC.

OBJECTIVES: To compare the efficacy of a novel silver nitrate-eluting indwelling pleural catheter (SNCIPC) with that of a standard, uncoated catheter.

METHODS: The SWIFT trial was a multicentre, parallel-group, randomised, controlled, patient-blind trial. Central randomisation occurred following a computer-generated schedule, stratified by site. Recruitment was from 17 secondary or tertiary-care hospitals in the USA and 3 in the UK and included adult patients with malignant pleural effusion needing drainage, without evidence of lung entrapment or significant loculation. The intervention group underwent insertion of a SNCIPC with maximal fluid drainage, followed by a tapering drainage schedule. The control group received a standard, uncoated catheter. Follow up was until 90 days. The primary outcome measure was pleurodesis efficacy, measured by fluid drainage, at 30 days.

RESULTS: 119 patients were randomised. 5 withdrew before receiving treatment, leaving 114 (77 SNCIPC, 37 standard IPC) for intention-to-treat analysis. Mean age was 66 years (SD 11). More patients in the SNCIPC group were in-patients (39% vs 14%, p=0.009). For the primary outcome, pleurodesis rates were 12/37 (32%) in the control group and 17/77 (22%) in the SNCIPC group (rate difference -0.10, 95% CI -0.30-0.09). Median time to pleurodesis was 11 days (IQR 9-23) in the control group and 4 days (IQR 2-15) in the SNCIPC group. No significant difference in treatment-related adverse event rates was noted between groups.

CONCLUSIONS: The SNCIPC did not improve pleurodesis efficacy compared to a standard indwelling pleural catheter. This study does not support the wider use of the SNCIPC device. Clinical trial registered with ClinicalTrials.gov (NCT02649894).

Original language	English
Pages (from-to)	1722–1729
Number of pages	8
Journal	Annals of the American Thoracic Society
Volume	19
Issue number	10
Early online date	1 Apr 2022
DOIs	https://doi.org/10.1513/AnnalsATS.202111-1301OC
Publication status	Published - 1 Oct 2022

Bibliographical note

Funding Information:
Supported by Becton, Dickinson and Company.

Funding Information:
The authors acknowledge all involved in the development and execution of this complex trial: the investigators and coordinators at all 20 sites; the data safety monitoring board (Drs. Richard Chiacchierini, Saeid Khansarinia, and Bert O'Neil); Chiltern International, Inc., for trial oversight; and the cross-functional new product development team at Becton, Dickinson and Co.

Publisher Copyright:
© 2022 by the American Thoracic Society.

Research Groups and Themes

Academic Respiratory Unit

Access to Document

10.1513/AnnalsATS.202111-1301OC

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via American Thoracic Society at https://doi.org/10.1513/AnnalsATS.202111-1301OC . Please refer to any applicable terms of use of the publisher.
Final published version, 665 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

Shrager, J. B., Bhatnagar, R., Kearney, C. T., Retzlaff, N. P., Cohen, E., Stanton, A. E., Keyes, C., Wahidi, M. M., Gillespie, C., Rahman, N., Kerry, A. L., Feller-Kopman, D., Nader, D., Akulian, J., Chen, A., Berry, M., Majid, A., Reddy, C., Tremblay, A., & Maskell, N. A. (2022). Silver Nitrate-Coated Versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial. Annals of the American Thoracic Society, 19(10), 1722–1729. https://doi.org/10.1513/AnnalsATS.202111-1301OC

@article{35165445adff4dd3b8e033803a33e33c,

title = "Silver Nitrate-Coated Versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial",

abstract = "RATIONALE: Tunneled, indwelling pleural catheters (IPC) have been demonstrated to be an effective method of managing malignant pleural effusions. However, they allow pleurodesis and can therefore be removed in only a subset of patients. A novel, silver-nitrate coated IPC was developed with the intention of creating a rapid, effective chemical pleurodesis to allow more frequent and earlier catheter removal. This study represent the pivotal clinical trial evaluating that catheter vs the standard IPC.OBJECTIVES: To compare the efficacy of a novel silver nitrate-eluting indwelling pleural catheter (SNCIPC) with that of a standard, uncoated catheter.METHODS: The SWIFT trial was a multicentre, parallel-group, randomised, controlled, patient-blind trial. Central randomisation occurred following a computer-generated schedule, stratified by site. Recruitment was from 17 secondary or tertiary-care hospitals in the USA and 3 in the UK and included adult patients with malignant pleural effusion needing drainage, without evidence of lung entrapment or significant loculation. The intervention group underwent insertion of a SNCIPC with maximal fluid drainage, followed by a tapering drainage schedule. The control group received a standard, uncoated catheter. Follow up was until 90 days. The primary outcome measure was pleurodesis efficacy, measured by fluid drainage, at 30 days.RESULTS: 119 patients were randomised. 5 withdrew before receiving treatment, leaving 114 (77 SNCIPC, 37 standard IPC) for intention-to-treat analysis. Mean age was 66 years (SD 11). More patients in the SNCIPC group were in-patients (39\% vs 14\%, p=0.009). For the primary outcome, pleurodesis rates were 12/37 (32\%) in the control group and 17/77 (22\%) in the SNCIPC group (rate difference -0.10, 95\% CI -0.30-0.09). Median time to pleurodesis was 11 days (IQR 9-23) in the control group and 4 days (IQR 2-15) in the SNCIPC group. No significant difference in treatment-related adverse event rates was noted between groups.CONCLUSIONS: The SNCIPC did not improve pleurodesis efficacy compared to a standard indwelling pleural catheter. This study does not support the wider use of the SNCIPC device. Clinical trial registered with ClinicalTrials.gov (NCT02649894).",

author = "Shrager, \{Joseph B\} and Rahul Bhatnagar and Kearney, \{Christine T\} and Retzlaff, \{Nathan P\} and Evan Cohen and Stanton, \{Andrew E\} and Colleen Keyes and Wahidi, \{Momen M\} and Colin Gillespie and Najib Rahman and Kerry, \{Anthony L\} and David Feller-Kopman and Daniel Nader and Jason Akulian and Alex Chen and Mark Berry and Adnan Majid and Chakravarthy Reddy and Alain Tremblay and Maskell, \{Nick A\}",

note = "Funding Information: Supported by Becton, Dickinson and Company. Funding Information: The authors acknowledge all involved in the development and execution of this complex trial: the investigators and coordinators at all 20 sites; the data safety monitoring board (Drs. Richard Chiacchierini, Saeid Khansarinia, and Bert O'Neil); Chiltern International, Inc., for trial oversight; and the cross-functional new product development team at Becton, Dickinson and Co. Publisher Copyright: {\textcopyright} 2022 by the American Thoracic Society.",

year = "2022",

month = oct,

day = "1",

doi = "10.1513/AnnalsATS.202111-1301OC",

language = "English",

volume = "19",

pages = "1722–1729",

journal = "Annals of the American Thoracic Society",

issn = "2329-6933",

publisher = "Oxford University Press",

number = "10",

}

Shrager, JB, Bhatnagar, R, Kearney, CT, Retzlaff, NP, Cohen, E, Stanton, AE, Keyes, C, Wahidi, MM, Gillespie, C, Rahman, N, Kerry, AL, Feller-Kopman, D, Nader, D, Akulian, J, Chen, A, Berry, M, Majid, A, Reddy, C, Tremblay, A & Maskell, NA 2022, 'Silver Nitrate-Coated Versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial', Annals of the American Thoracic Society, vol. 19, no. 10, pp. 1722–1729. https://doi.org/10.1513/AnnalsATS.202111-1301OC

TY - JOUR

T1 - Silver Nitrate-Coated Versus Standard Indwelling Pleural Catheter for Malignant Effusions

T2 - The SWIFT Randomized Trial

AU - Shrager, Joseph B

AU - Bhatnagar, Rahul

AU - Kearney, Christine T

AU - Retzlaff, Nathan P

AU - Cohen, Evan

AU - Stanton, Andrew E

AU - Keyes, Colleen

AU - Wahidi, Momen M

AU - Gillespie, Colin

AU - Rahman, Najib

AU - Kerry, Anthony L

AU - Feller-Kopman, David

AU - Nader, Daniel

AU - Akulian, Jason

AU - Chen, Alex

AU - Berry, Mark

AU - Majid, Adnan

AU - Reddy, Chakravarthy

AU - Tremblay, Alain

AU - Maskell, Nick A

N1 - Funding Information: Supported by Becton, Dickinson and Company. Funding Information: The authors acknowledge all involved in the development and execution of this complex trial: the investigators and coordinators at all 20 sites; the data safety monitoring board (Drs. Richard Chiacchierini, Saeid Khansarinia, and Bert O'Neil); Chiltern International, Inc., for trial oversight; and the cross-functional new product development team at Becton, Dickinson and Co. Publisher Copyright: © 2022 by the American Thoracic Society.

PY - 2022/10/1

Y1 - 2022/10/1

N2 - RATIONALE: Tunneled, indwelling pleural catheters (IPC) have been demonstrated to be an effective method of managing malignant pleural effusions. However, they allow pleurodesis and can therefore be removed in only a subset of patients. A novel, silver-nitrate coated IPC was developed with the intention of creating a rapid, effective chemical pleurodesis to allow more frequent and earlier catheter removal. This study represent the pivotal clinical trial evaluating that catheter vs the standard IPC.OBJECTIVES: To compare the efficacy of a novel silver nitrate-eluting indwelling pleural catheter (SNCIPC) with that of a standard, uncoated catheter.METHODS: The SWIFT trial was a multicentre, parallel-group, randomised, controlled, patient-blind trial. Central randomisation occurred following a computer-generated schedule, stratified by site. Recruitment was from 17 secondary or tertiary-care hospitals in the USA and 3 in the UK and included adult patients with malignant pleural effusion needing drainage, without evidence of lung entrapment or significant loculation. The intervention group underwent insertion of a SNCIPC with maximal fluid drainage, followed by a tapering drainage schedule. The control group received a standard, uncoated catheter. Follow up was until 90 days. The primary outcome measure was pleurodesis efficacy, measured by fluid drainage, at 30 days.RESULTS: 119 patients were randomised. 5 withdrew before receiving treatment, leaving 114 (77 SNCIPC, 37 standard IPC) for intention-to-treat analysis. Mean age was 66 years (SD 11). More patients in the SNCIPC group were in-patients (39% vs 14%, p=0.009). For the primary outcome, pleurodesis rates were 12/37 (32%) in the control group and 17/77 (22%) in the SNCIPC group (rate difference -0.10, 95% CI -0.30-0.09). Median time to pleurodesis was 11 days (IQR 9-23) in the control group and 4 days (IQR 2-15) in the SNCIPC group. No significant difference in treatment-related adverse event rates was noted between groups.CONCLUSIONS: The SNCIPC did not improve pleurodesis efficacy compared to a standard indwelling pleural catheter. This study does not support the wider use of the SNCIPC device. Clinical trial registered with ClinicalTrials.gov (NCT02649894).

AB - RATIONALE: Tunneled, indwelling pleural catheters (IPC) have been demonstrated to be an effective method of managing malignant pleural effusions. However, they allow pleurodesis and can therefore be removed in only a subset of patients. A novel, silver-nitrate coated IPC was developed with the intention of creating a rapid, effective chemical pleurodesis to allow more frequent and earlier catheter removal. This study represent the pivotal clinical trial evaluating that catheter vs the standard IPC.OBJECTIVES: To compare the efficacy of a novel silver nitrate-eluting indwelling pleural catheter (SNCIPC) with that of a standard, uncoated catheter.METHODS: The SWIFT trial was a multicentre, parallel-group, randomised, controlled, patient-blind trial. Central randomisation occurred following a computer-generated schedule, stratified by site. Recruitment was from 17 secondary or tertiary-care hospitals in the USA and 3 in the UK and included adult patients with malignant pleural effusion needing drainage, without evidence of lung entrapment or significant loculation. The intervention group underwent insertion of a SNCIPC with maximal fluid drainage, followed by a tapering drainage schedule. The control group received a standard, uncoated catheter. Follow up was until 90 days. The primary outcome measure was pleurodesis efficacy, measured by fluid drainage, at 30 days.RESULTS: 119 patients were randomised. 5 withdrew before receiving treatment, leaving 114 (77 SNCIPC, 37 standard IPC) for intention-to-treat analysis. Mean age was 66 years (SD 11). More patients in the SNCIPC group were in-patients (39% vs 14%, p=0.009). For the primary outcome, pleurodesis rates were 12/37 (32%) in the control group and 17/77 (22%) in the SNCIPC group (rate difference -0.10, 95% CI -0.30-0.09). Median time to pleurodesis was 11 days (IQR 9-23) in the control group and 4 days (IQR 2-15) in the SNCIPC group. No significant difference in treatment-related adverse event rates was noted between groups.CONCLUSIONS: The SNCIPC did not improve pleurodesis efficacy compared to a standard indwelling pleural catheter. This study does not support the wider use of the SNCIPC device. Clinical trial registered with ClinicalTrials.gov (NCT02649894).

U2 - 10.1513/AnnalsATS.202111-1301OC

DO - 10.1513/AnnalsATS.202111-1301OC

M3 - Article (Academic Journal)

C2 - 35363591

SN - 2329-6933

VL - 19

SP - 1722

EP - 1729

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

IS - 10

ER -

Silver Nitrate-Coated Versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial

Abstract

Bibliographical note

Research Groups and Themes

Access to Document

Handle.net

Fingerprint

Cite this